Recombinant Factor VII for Intractable Postpartum Haemorrhage

Postpartum haemorrhage remains at the top of the causes of maternal deaths in both developed and developing countries .

Completed

Looking for future studies?

Key information

Conditions

Post Partum Hemorrhage Female Urogenital Diseases and Pregnancy Complications Hemorrhage Obstetric Labor Complications Pathologic Processes Pathological Conditions, Signs and Symptoms Postpartum Hemorrhage Pregnancy Complications Puerperal Disorders Urogenital Diseases Uterine Hemorrhage

Age range

18 year–45 year

Sex eligibility

Female

Study type

Observational

Primary location

Doaaa Alaa

Cairo, Egypt

About this study

Major postpartum haemorrhage is a dangerous complication that accounts for the highest maternal morbidity rate

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Women with severe resistant postpartum hemorage

Exclusion criteria

women without postpartum hemorage

Treatment and study plan

Recombinant Factor VIIa

Drug

using recombinant factor VIIa

Primary outcomes

The number of women who had hysterectomy

Time frame: 24 hours

number of women resistant to the treatment and needed hysterectomy

Sponsors and collaborators

Lead sponsor

Aljazeera Hospital

Other

Registry information

Official study title

Recombinant Factor VII for the Conservative Management Trials of Intractable Postpartum Haemorrhage: is it a Drug Effect , Operator Experience or Inherent Result of the Aetiology.

Important dates

Study start: 2019
Primary completion: 2020
Study completion: 2020
First posted: Mar 28, 2022
Registry last updated: Mar 28, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed